Radiopharmacy firm Syncor International of Woodland Hills, CA, has agreed to license its technology to Israeli nuclear research agency Soreq and its subsidiary, Isorad, which plan to establish a radiopharmacy in Israel. In exchange for providing
Radiopharmacy firm Syncor International of Woodland Hills, CA, has agreed to license its technology to Israeli nuclear research agency Soreq and its subsidiary, Isorad, which plan to establish a radiopharmacy in Israel. In exchange for providing information and technical assistance to set up the radiopharmacy, Syncor will receive quarterly payments. Soreq is affiliated with the Israel Atomic Energy Commission and carries out advanced R&D projects, while Isorad sells and markets Soreq products to private businesses.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.